- Details
- Jason Hafron, MD, joins Alicia Morgans, MD, MPH in a conversation on operationalizing genomic testing in clinical practice, towards supporting the use of PARP inhibitors in the appropriate patients. Dr. Hafron emphasizes the key to this success begins with the implementation of clinical pathways. With streamlined accurate clinical pathways, we can speed up the process and provide care to the patie...
|
- Details
- In May 2020, the United States Food and Drug Administration approved olaparib for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. Efficacy was investigated in the PROfound study, a pr...
|
- Details
- Joining Alicia Morgans, MD, MPH, is Pedro Barata, MD, MSc, a co-author of the paper titled, "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability-high (MSI-H) detected by circulating tumor DNA." Dr. Barata provides the background behind the multi-institutional case series explaining that the use of liquid biopsy in identifying metastatic prostate cancer...
|
- Details
- Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss the US Federal Drug Administration (FDA) recent approval of the FoundationOne® Liquid CDx biopsy test that informs precision medicine in mCRPC. This is a companion diagnostic that serves as a predictive biomarker to identify patients who may benefit from targeted therapies including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibito...
|
- Details
- Colin Pritchard, MD, PhD, Heather Cheng, MD, PhD, and Petros Grivas, MD, PhD, join Alicia Morgans, MD, MPH, to discuss the increasing role of molecular diagnostics and testing in genitourinary cancers. Dr. Pritchard begins by highlighting the advantages of the University of Washington and Seattle Cancer Care Alliance’s GU molecular tumor board. By providing clinicians the opportunity to discuss tu...
|
- Details
- Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans to discuss the ProGen study. A randomized controlled trial that aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer. This...
|
- Details
- Hala Borno joins Alicia Morgans and discusses a recent viewpoint article in JAMA Oncology titled “The Ethics of Delivering Precision Medicine—Pretest Counseling and Somatic Genomic Testing.” In the new era of precision medicine in cancer treatment, many clinicians use patient tumor genomic (somatic) data as part of routine clinical practice. Dr. Borno shares insights into Pretest Counseling in an...
|
- Details
- Together with Alicia Morgans, Maria Carlo delves into the topic of germline testing for patients with genitourinary malignancies. In a more non-traditional approach to investigating the effects of DNA repair defects on prostate and bladder cancer, Carlo factors in not only oncological outcomes, but also psychological outcomes of her clinical trials. Biographies: Maria Carlo, MD, Medical Oncologist...
|
- Details
- Brian Helfand presents the use of genomics today to personalize the treatment of men with prostate cancer and the different models on how to implement this testing in your clinic. There are not enough genetic counselors throughout the country to answer everyone's needs, so it is important as a urologist to start initiating these conversations with patients. Biographies: Brian T. Helfand, M.D., Ph....
|
- Details
- Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...
|
